Case Counts
The Infectious Diseases & Outbreaks Division monitors the incidence and prevalence of communicable, zoonotic, and environmentally-related human diseases. This table summarizes cases reported over the last five years, as well as the cases reported year-to-date this year and last year.
|
|
Cases Reported Year-to-Date* |
Totals by Year Reported |
||||||
Condition |
2021 |
2020 |
% Change |
2020 |
2019 |
2018 |
2017 |
2016 |
|
Acute Flaccid Myelitis |
0 |
0^ |
-- |
0^ |
0^ |
-- |
-- |
-- |
|
Anthrax |
0 |
0 |
-- |
0 |
0 |
0^ |
0 |
0 |
|
Arboviral Diseases (excludes Chikungunya virus, Dengue, and Zika virus) |
2 |
0 |
-- |
10 |
6 |
28 |
62 |
18^ |
|
Babesiosis |
0 |
1 |
-100.0% |
1 |
0 |
0 |
1 |
0 |
|
Botulism |
0 |
0 |
-- |
1 |
1 |
0 |
0 |
1 |
|
Brucellosis |
0 |
0 |
-- |
1 |
4 |
1 |
0 |
0 |
|
Campylobacteriosis |
281 |
245 |
14.7% |
662 |
754 |
783 |
790 |
692 |
|
Chikungunya virus |
0 |
0 |
-- |
0 |
0 |
0 |
1 |
1^ |
|
Cholera |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Coccidioidomycosis |
3 |
2 |
50.0% |
5 |
9 |
-- |
-- |
-- |
|
Cryptosporidiosis |
39 |
66 |
-40.9% |
137 |
225 |
152 |
189 |
334 |
|
Cyclosporiasis |
0 |
0 |
-- |
9 |
5 |
-- |
-- |
-- |
|
Dengue |
0 |
0 |
-- |
0 |
3 |
2 |
0 |
5 |
|
E. coli, shiga toxin-producing (includes O157: H7) |
37 |
27 |
37.0% |
100 |
138 |
129^ |
31 |
39 |
|
Ehrlichiosis/Anaplasmosis |
7 |
5 |
40.0% |
12 |
39 |
24 |
17 |
21 |
|
Giardiasis |
55 |
41 |
34.1% |
130 |
164 |
217 |
191 |
234 |
|
Hansen's Disease (Leprosy) |
0 |
1 |
-100.0% |
1 |
1 |
0 |
1 |
1 |
|
Hantavirus Pulmonary Syndrome |
0 |
0 |
-- |
0 |
0 |
-- |
-- |
-- |
|
Hemolytic uremic syndrome (HUS) |
1 |
2 |
-50.0% |
3 |
6 |
3 |
0 |
6 |
|
Hepatitis E, acute |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Influenza-associated non-pediatric mortality |
24 |
13 |
84.6% |
19 |
93 |
257 |
-- |
-- |
|
Influenza-associated pediatric mortality |
0 |
1 |
-100.0% |
1 |
2 |
2 |
1 |
0 |
|
Legionellosis |
29 |
23 |
26.1% |
61 |
72 |
76 |
66 |
63 |
|
Leptospirosis |
0 |
0 |
-- |
0 |
0 |
1 |
0 |
0 |
|
Listeriosis |
5 |
7 |
-28.6% |
14 |
7^ |
11 |
5 |
8 |
|
Lyme disease |
15 |
5 |
200.0% |
15 |
66 |
36 |
39^ |
38 |
|
Malaria |
0 |
2 |
-100.0% |
2 |
9 |
9 |
8 |
10 |
|
Novel Influenza A virus infection |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Paratyphoid Fever |
0 |
1 |
-100.0% |
2 |
0^ |
6^ |
3 |
9 |
|
Plague |
0 |
0^ |
-- |
0^ |
0 |
0 |
0 |
0 |
|
Psittacosis |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Q fever |
1 |
0 |
-- |
0 |
2 |
2 |
0 |
1 |
|
Rabies, animal |
15 |
29 |
-48.3% |
50 |
50 |
55 |
51 |
77 |
|
Rabies, human |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Salmonellosis |
209 |
218 |
-4.1% |
881 |
1001 |
1198^ |
1129^ |
1276 |
|
Severe Acute Respiratory Syndrome-associated Coronavirus (SARS-CoV) |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Shigellosis |
25 |
302 |
-91.7% |
342 |
431 |
320 |
247^ |
239 |
|
Smallpox |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Spotted Fever Rickettsiosis |
35 |
29 |
20.7% |
90 |
476^ |
673 |
671 |
453 |
|
Toxic Shock Syndrome (non-streptococcal) |
0 |
0 |
-- |
0 |
0 |
-- |
-- |
-- |
|
Trichinellosis (Trichinosis) |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
Tularemia |
0 |
0 |
-- |
1 |
4 |
0 |
1^ |
1 |
|
Typhoid fever |
1 |
0 |
-- |
1 |
0^ |
1 |
1 |
0 |
|
Vibriosis (non-Cholera) |
8 |
10 |
-20.0% |
26 |
41 |
38 |
26^ |
31 |
|
Viral hemorrhagic fever |
0 |
0 |
-- |
0 |
0 |
0 |
0 |
0 |
|
VISA (Staphylococcus aureus, vancomycin-intermediate) |
1 |
0 |
-- |
0 |
1 |
1 |
4 |
3 |
|
VRSA (Staphylococcus aureus, vancomycin-resistant) |
0 |
1 |
-100.0% |
1 |
2 |
0 |
0 |
0 |
|
Yellow Fever |
0 |
0 |
-- |
0 |
0^ |
0 |
0 |
0 |
|
Zika virus |
0 |
0 |
-- |
0 |
0 |
3 |
4 |
41^ |
|
Other Investigations |
1 |
0 |
-- |
0 |
3 |
0 |
0 |
0 |
Total |
794 |
1031 |
-23.0% |
2578 |
3615 |
4028 |
3539 |
3602 |
|
NOTE: Counts include finalized investigations among Alabama residents as of June 16, 2021. The Other investigations category includes a variety of conditions or events that have been investigated, but are not reportable in Alabama or do not fall into any other category (e.g., Histoplasmosis, Streptococcal toxic-shock syndrome, Yersiniosis, etc.). To see case counts for conditions investigated by other divisions, please see the following websites: Tuberculosis, Immunizations, Sexually Transmitted Diseases, and HIV/AIDS. |
||||||||
|
*Through MMWR Week 23 (week ending June 12, 2021), as compared to the same time period in the previous calendar year. |
||||||||
|
^The case definition was updated this year for this condition. |
||||||||
Page last updated: June 16, 2021
